Annamaria Molino, MD

Articles by Annamaria Molino, MD

Gemcitabine/Epirubicin/Paclitaxel Trials in Advanced Breast Cancer

ByPierfranco Conte, MD,Barbara Salvadori, MD,Sara Donati, MD,Alessandra Gennari, MD,Gian Luigi Cetto, MD,Annamaria Molino, MD,Lucio CrinÒ, MD,Francesca Mazzoni, MD,Enzo Galligioni, MD,Maurizio Mansutti, MD

February 1st 2001

Numerous trials have shown that the pharmacokinetic interferences of epirubicin (Ellence)/paclitaxel (Taxol) combinations produce less pharmacodynamic effect than doxorubicin/paclitaxel regimens. Paclitaxel is more easily

Latest Updated Articles

Gemcitabine/Epirubicin/Paclitaxel Trials in Advanced Breast Cancer
Published: February 1st 2001 | Updated:

Annamaria Molino, MD

Articles by Annamaria Molino, MD

Gemcitabine/Epirubicin/Paclitaxel Trials in Advanced Breast Cancer

Latest Updated Articles

Trending on CancerNetwork

Serplulimab Plus Chemo Meets EFS End Point in Early-Stage Gastric Cancer

CD20 Bispecifics vs CAR T: Evaluating CRS and ICANS in Lymphoma

KRd Appears to Exhibit Greater Outcomes in Standard-Risk Multiple Myeloma

ADCE-D01 Earns FDA Fast Track Designation in Soft Tissue Sarcoma

KRd-Based Quadruplets May “Eliminate” Transplant Need for Multiple Myeloma